Andere Sprachen Revive Therapeutics Ltd.

Aktien

A2AP4F

CA7615161030

RVV

Markt geschlossen - Canadian Securities Exchange Andere Börsenplätze 19:23:32 26.04.2024			% 5 Tage	% 1. Jan.
0,03 ^CAD	+20,00 %		0,00 %	0,00 %

18.04.	Revive Therapeutics Ltd. gibt bekannt, dass die FDA den Antrag auf ein Treffen für das lange COVID-Diagnoseprodukt akzeptiert hat	CI
02.04.	Revive Therapeutics Ltd. gibt Update zur klinischen Psilocybin-Studie zur Methamphetaminabhängigkeit	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID	23.04.
Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	23.04.
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	23.04.
Revive Therapeutics Announced FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18.04.
Revive Therapeutics Brief: Announcing FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18.04.
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18.04.
Revive Therapeutics Ltd. Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18.04.
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02.04.
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02.04.
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02.04.
Revive Therapeutics Ltd. Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02.04.
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	27.03.
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	27.03.
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	27.03.
Revive Therapeutics : Document	20.03.
Revive Therapeutics : Document	20.03.
Revive Therapeutics to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	19.03.
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	19.03.
Revive Therapeutics Ltd. Announces to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	19.03.
Revive Therapeutics Provides Corporate Update	12.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Revive Therapeutics Ltd.

Aktien

A2AP4F

CA7615161030

RVV

Andere Sprachen

Filter